- Investing.com
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Metrics to compare | SERA | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipSERAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −2.7x | −0.5x | |
PEG Ratio | −0.09 | −0.10 | 0.00 | |
Price/Book | 0.9x | 2.7x | 2.6x | |
Price / LTM Sales | 852.9x | 8.6x | 3.1x | |
Upside (Analyst Target) | 161.8% | 68.6% | 55.6% | |
Fair Value Upside | Unlock | 14.2% | 8.6% | Unlock |